These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 33875889)
1. Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populations. Zard M; Lau LS; Bowser DM; Fouad FM; Lucumà DI; Samari G; Harker A; Shepard DS; Zeng W; Moresky RT; Audi MN; Greene CM; Kachur SP Nat Med; 2021 May; 27(5):747-749. PubMed ID: 33875889 [TBL] [Abstract][Full Text] [Related]
2. Ensuring equitable access to vaccines for refugees and migrants during the COVID-19 pandemic. Bartovic J; Datta SS; Severoni S; D'Anna V Bull World Health Organ; 2021 Jan; 99(1):3-3A. PubMed ID: 33658728 [No Abstract] [Full Text] [Related]
3. Ensuring global access to COVID-19 vaccines: deployment strategies for refugees and migrants must not be forgotten. Buonsenso D; von Both U Infection; 2022 Feb; 50(1):273-275. PubMed ID: 34047954 [No Abstract] [Full Text] [Related]
4. Statelessness in the COVID-19 pandemic. Burki T Lancet; 2021 Apr; 397(10284):1529-1530. PubMed ID: 33894821 [No Abstract] [Full Text] [Related]
5. COVID-19 Vaccine Distribution in a Community With Large Numbers of Immigrants and Refugees. Malone B; Kim E; Jennings R; Pacheco RA; Kieu A Am J Public Health; 2022 Mar; 112(3):393-396. PubMed ID: 35196045 [TBL] [Abstract][Full Text] [Related]
7. Impact of COVID-19 on migrants and refugees. Balakrishnan VS Lancet Infect Dis; 2021 Aug; 21(8):1076-1077. PubMed ID: 34331881 [No Abstract] [Full Text] [Related]
8. Equitable distribution of COVID-19 vaccines. Burki T Lancet Infect Dis; 2021 Jan; 21(1):33-34. PubMed ID: 33357392 [No Abstract] [Full Text] [Related]
9. Vaccine design and delivery approaches for COVID-19. Shahzamani K; Mahmoudian F; Ahangarzadeh S; Ranjbar MM; Beikmohammadi L; Bahrami S; Mohammadi E; Esfandyari S; Alibakhshi A; Javanmard SH Int Immunopharmacol; 2021 Nov; 100():108086. PubMed ID: 34454291 [TBL] [Abstract][Full Text] [Related]
10. Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. Su S; Shao Y; Jiang S Emerg Microbes Infect; 2021 Dec; 10(1):439-441. PubMed ID: 33635184 [No Abstract] [Full Text] [Related]
11. COVID-19 Vaccines: Ensuring Social Justice and Health Equity among Refugees in Africa. Manirambona E; Hague O; Trajano LF; Killen A; Wilkins L; Nkeshimana M; Lucero-Prisno Iii DE Ann Glob Health; 2021; 87(1):106. PubMed ID: 34786354 [TBL] [Abstract][Full Text] [Related]
13. Vaccines for SARS coronavirus 2 and the new normal in vaccinology. Griffiths PD Rev Med Virol; 2021 Mar; 31(2):e2229. PubMed ID: 33666285 [No Abstract] [Full Text] [Related]
14. COVID-19 vaccines and kidney disease. Windpessl M; Bruchfeld A; Anders HJ; Kramer H; Waldman M; Renia L; Ng LFP; Xing Z; Kronbichler A Nat Rev Nephrol; 2021 May; 17(5):291-293. PubMed ID: 33558753 [TBL] [Abstract][Full Text] [Related]
15. Vaccine development for emerging infectious diseases. Excler JL; Saville M; Berkley S; Kim JH Nat Med; 2021 Apr; 27(4):591-600. PubMed ID: 33846611 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough. Rubin R JAMA; 2021 Apr; 325(13):1241-1243. PubMed ID: 33729423 [No Abstract] [Full Text] [Related]